Opioid Use Disorder and Treatment Uptake Among Patients With Rheumatic Conditions in the All of Us Research Program: A Descriptive Analysis
Authors' conclusion
Patients with rheumatic conditions and OUD exhibit distinct demographic and clinical characteristics including lower DMARD use and higher acute care use. MOUD uptake (14.5%) was significantly lower than national estimates (25%).
Study context
- Population
- Individuals with at least two billing codes for systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), spondyloarthritis (SpA) or osteoarthritis (OA) in the All of Us Research Program
- Participants
- 37,282 individuals
- Exposure
- Patients with vs without opioid use disorder (OUD)
- OUDn = 1,502
- Outcome
- Characteristics of patients with rheumatic conditions who have OUD and their uptake of MOUDs
Methodological detailsdescriptive analysis, national All of Us Research Program (version 8)
- Descriptive analysis
- National All of Us Research Program (version 8)
Main finding
As reported in the abstract
| Group | Value | Received MOUDs |
|---|---|---|
| OUD | 4% | 14.5% |
OUD
Value4%
Received MOUDs14.5%
Observational data: associations, not effects.
Further findings
- Prior prescription opioids, with vs without OUD
- 75.7% vs 45.8%
- Patients with vs without OUD more likely to have received glucocorticoids but less likely to have used biologic, targeted synthetic or conventional DMARDs
- Patients with vs without OUD younger, more likely to have Medicaid insurance, psychiatric and medical comorbidities, and higher acute care use
Original publication
Opioid Use Disorder and Treatment Uptake Among Patients With Rheumatic Conditions in the All of Us Research Program: A Descriptive Analysis. Arthritis Care Res (Hoboken). Published 13 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →